×
About 750,608 results

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
https://doi.org/10.1002/art.41752
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...

Fluconazole - fluconazole tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11e0926-cd15-49ba-b0ee-2b6d4e009dd8

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat-to-target strategy, and use of imaging. New q...

Cortrosyn - cosyntropin injection, powder, lyophilized, for solution-Amphastar Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=746856e9-3930-4f6a-b8e6-a03845d6dd0b

Dec 1st, 2022 - CORTROSYN® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION ...

Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
https://acrabstracts.org/abstract/chimeric-autoantigen-t-cell-receptor-catcr-t-cell-therapies-to-selectively-target-autoreactive-b-cells/
Brian J. Mog, Elana R. Shaw, Michael S. Hwang et. al.

Nov 14th, 2022 - Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment of refractory autoimmune diseases, but therapies that indiscriminately deplete all B cells are limited by infection risk. In contrast, precision immunotherapies that selectively eliminate autoreactive B cel...

Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma
https://acrabstracts.org/abstract/phase-ii-clinical-trial-to-assess-the-safety-and-efficacy-of-tocilizumab-in-combination-with-ipilimumab-and-nivolumab-for-treatment-naive-metastatic-melanoma/
Noha Abdel-Wahab, Emma J. Montazari, Christine A. Spillson et. al.

Nov 14th, 2022 - Background/Purpose: Immune checkpoint inhibitors (ICIs) led to impressive survival benefits in treatment of cancers. However, immune-related adverse events (irAEs) can cause treatment discontinuation and sometimes fatalities, more often seen with combination ICIs. Through nanostring gene expression profiling of colitis-irAE, normal colon, and tumor biopsies, we found that the interleukin-6 (IL-...

Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
https://acrabstracts.org/abstract/hydroxychloroquine-dosing-less-than-5-mg-kg-day-leads-to-increased-hospitalizations-for-systemic-lupus-erythematosus-flares/
Jacquelyn Nestor, Christian Mancini, Baijun Zhou et. al.

Nov 14th, 2022 - Background/Purpose: Hydroxychloroquine (HCQ) is the backbone of SLE therapy, due to its benefits on increasing survival and decreasing lupus flares. In 2011, ophthalmology guidelines recommended limiting HCQ dosing to ≤6.5mg/kg of ideal body weight to reduce the risk of retinopathy; in 2016 updated guidelines recommended using ≤5mg/kg of actual body weight. For many patients, these guidelines r...

Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
https://acrabstracts.org/abstract/long-term-safety-and-efficacy-of-anifrolumab-in-adult-patients-with-systemic-lupus-erythematosus-a-multicenter-randomized-double-blind-placebo-controlled-3-year-tulip-extension-study/
Kenneth C. Kalunian, Richard A. Furie, Eric F. Morand et. al.

Nov 14th, 2022 - Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody that binds to the type I IFN receptor and inhibits type I IFN signaling.1 In the phase 3, randomized, double-blind, placebo-controlled TULIP-1 (NCT02446912)2 and TULIP-2 (NCT02446899)3 trials, demonstration of a favorable benefit–risk profile led to approval of anifrolumab in several countries for patients with moderate...

Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort
https://acrabstracts.org/abstract/long-term-renal-survival-of-patients-with-ln-by-renal-response-status-in-the-toronto-lupus-cohort/
Murray Urowitz, Mary E. Georgiou, Jiandong Su et. al.

Nov 14th, 2022 - Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials as a measure of treatment efficacy in patients with LN; however, there are various definitions of renal response and limited evidence to support whether it accurately predicts long-term renal outcomes. A study using data from ...

Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
https://acrabstracts.org/abstract/phospholipase-d-4-is-a-novel-surface-marker-of-a-distinctive-b-cell-population-overlapping-with-double-negative-2-b-cells/
Ken Yasaka, Tomohide Yamazaki, Hiroko Sato et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with minimal adverse effects and dependence on corticosteroids. Some phenotypically distinct B cell populations including IgD-, CD27-, CD11c+, and CXCR5lo double negative 2 (DN2) B cells, are expanded ...

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
https://acrabstracts.org/abstract/medication-cost-concerns-and-disparities-in-patient-reported-outcomes-among-a-multiethnic-cohort-of-patients-with-lupus/
Alfredo Aguirre, Kimberly DeQuattro, Patricia Katz et. al.

Nov 14th, 2022 - Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to one-fifth of patients with systemic lupus erythematosus (SLE), but little is known about the relationship between these concerns and relevant health outcomes. In a multiethnic cohort of patients with SLE, we ass...

Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
https://acrabstracts.org/abstract/metformin-improves-objective-measures-of-dry-eyes-and-focus-score-in-sjogren%E2%80%B2s-disease-a-retrospective-observational-study/
Astrid Rasmussen, R. Hal Scofield, Kiely Grundahl et. al.

Nov 14th, 2022 - Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in SLE and multiple sclerosis have shown that Met associates with reduced Th17 cells, IL-17, IL-1b, IL-6, IFN-g, and TNF-a, while restoring or increasing regulatory T-cells (Treg). Sjögren’s D...

Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Pl...
https://acrabstracts.org/abstract/bimekizumab-treatment-results-in-improvements-in-fatigue-and-pain-in-biologic-dmard-naive-or-tnfi-ir-patients-with-active-psoriatic-arthritis-pooled-16-week-results-from-two-phase-3-randomized-place/
M. Elaine Husni, Philip J Mease, Joseph Merola et. al.

Nov 14th, 2022 - Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated improvements in patient-reported symptoms up to 3 years in a phase 2b study.2 This analysis aimed to assess the impact of BKZ...

Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
https://acrabstracts.org/abstract/early-clinical-improvement-as-predictor-of-long-term-health-related-quality-of-life-in-psoriatic-arthritis-patients-treated-with-guselkumab-post-hoc-analysis-through-2-years-of-a-phase-3-study/
Iain B McInnes, Enrique R Soriano, Lai-shan Tam et. al.

Nov 14th, 2022 - Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight the importance of maximizing long‐term (LT) health‐related quality of life (HRQoL) and social participation as primary goals of therapy3. We aimed to determine whether early clinical improvement with guselku...

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conduct...
https://acrabstracts.org/abstract/long-term-efficacy-of-guselkumab-in-fatigue-and-identification-of-early-treatment-targets-post-hoc-analysis-through-2-years-of-a-phase-3-randomized-double-blind-placebo-controlled-study-conducted/
Dafna Gladman, Michael Starr, Roberto Ranza et. al.

Nov 14th, 2022 - Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA achievement2. In this post hoc analysis, the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) scale was used to: (a) evaluate the long-term effect of GUS in maintaining improv...

Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Random...
https://acrabstracts.org/abstract/stringent-disease-activity-control-at-2-years-across-psoriatic-arthritis-domains-irrespective-of-baseline-characteristics-in-patients-treated-with-guselkumab-post-hoc-analysis-of-a-phase-3-randomize/
Christopher Ritchlin, Philip J Mease, Wolf-Henning Boehncke et. al.

Nov 14th, 2022 - Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3 DISCOVER-1 and DISCOVER-2 (D2) trials, across a variety of baseline (BL) pt characteristics through 11, and 2 years (D2 only)2. In this post-hoc analysis using D2 data, we evaluated the efficacy of GUS in inducing long-term (W1...

A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
https://acrabstracts.org/abstract/a-prospective-study-on-long-term-clinical-outcomes-of-patients-with-lupus-nephritis-treated-with-an-intensified-b-cell-depletion-protocol-without-maintenance-therapy/
Dario Roccatello, Savino Sciascia, Carla Naretto et. al.

Nov 14th, 2022 - Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of care in biopsy-proven Lupus Nephritis (LN). Methods: Thirty patients were administered an IBCDT (4 weekly rituximab [RTX] 375 mg/m2 and 2 more doses after 1 and 2 months; 2 infusions of 10 mg/kg c...

Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Ne...
https://acrabstracts.org/abstract/hazard-index-equations-using-data-collected-at-baseline-and-after-one-year-treatment-allow-early-prediction-of-poor-outcome-in-an-incident-lupus-nephritis-population-data-from-the-louvain-lupus-nephr/
Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels et. al.

Nov 14th, 2022 - Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints predictive of long-term outcome in LN are therefore most welcome to compare efficacy of pharmacological interventions. A multicentric study, using a large database of prospectively followed LN patients, succeed...

Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
https://acrabstracts.org/abstract/sustained-b-cell-depletion-in-lupus-nephritis-patients-after-treatment-with-a-b-cell-agent-is-associated-with-fewer-disease-flares/
Diane Zisa, Jeffrey Zhang-Sun, Paul Christos2 and Kyriakos Kirou et. al.

Nov 14th, 2022 - Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients at highest risk for flare after receipt of these agents has not been well studied. We hypothesized that sustained low peripheral B cell counts (BCC) after successful control of LN would be associated with fewe...

Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
https://acrabstracts.org/abstract/does-early-complete-remission-preclude-adverse-outcomes-in-lupus-nephritis/
KONSTANTINOS TSELIOS, Dafna Gladman, Jiandong Su3 and Murray Urowitz et. al.

Nov 14th, 2022 - Background/Purpose: Background: Early complete remission (within 12 months from diagnosis) is considered an important protective factor against development of advanced chronic kidney disease (CKD) in lupus nephritis (LN). However, a certain proportion of such patients still develop advanced CKD and, eventually, end-stage renal disease (ESRD). Objective: To describe the factors associated with t...